Judith R Kroep
Judith R Kroep
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Actively personalized vaccination trial for newly diagnosed glioblastoma
N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ...
Nature 565 (7738), 240-245, 2019
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
S Chawla, R Henshaw, L Seeger, E Choy, JY Blay, S Ferrari, J Kroep, ...
The lancet oncology 14 (9), 901-908, 2013
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
JK Anninga, H Gelderblom, M Fiocco, JR Kroep, AHM Taminiau, ...
European journal of cancer 47 (16), 2431-2445, 2011
Basis for effective combination cancer chemotherapy with antimetabolites
GJ Peters, CL Van der Wilt, CJA Van Moorsel, JR Kroep, AM Bergman, ...
Pharmacology & therapeutics 87 (2-3), 227-253, 2000
Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment
EM Dijkgraaf, M Heusinkveld, B Tummers, LTC Vogelpoel, R Goedemans, ...
Cancer research 73 (8), 2480-2492, 2013
Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver
CL Van Der Wilt, JR Kroep, WJP Loves, MG Rots, CJ Van Groeningen, ...
European Journal of Cancer 39 (5), 691-697, 2003
The clinical approach toward giant cell tumor of bone
L Van der Heijden, PDS Dijkstra, MAJ van de Sande, JR Kroep, RA Nout, ...
The oncologist 19 (5), 550-561, 2014
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
PA Cassier, H Gelderblom, S Stacchiotti, D Thomas, RG Maki, JR Kroep, ...
Cancer 118 (6), 1649-1655, 2012
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
S de Groot, MPG Vreeswijk, MJP Welters, G Gravesteijn, JJWA Boei, ...
BMC cancer 15, 1-9, 2015
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer
S Van de Ven, V Smit, TJA Dekker, JWR Nortier, JR Kroep
Cancer treatment reviews 37 (6), 422-430, 2011
Pretreatment Deoxycytidine Kinase Levels Predict in Vivo Gemcitabine Sensitivity
JR Kroep, WJP Loves, CL Van Der Wilt, E Alvarez, I Talianidis, E Boven, ...
Molecular cancer therapeutics 1 (6), 371-376, 2002
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V Bossuyt, E Provenzano, WF Symmans, JC Boughey, C Coles, ...
Annals of oncology 26 (7), 1280-1291, 2015
Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy
EC Rijkmans, RA Nout, I Rutten, M Ketelaars, KJ Neelis, MS Laman, ...
Gynecologic oncology 135 (2), 231-238, 2014
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an …
JR Kroep, M Ouali, H Gelderblom, A Le Cesne, TJA Dekker, ...
Annals of oncology 22 (1), 207-214, 2011
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
S de Groot, RT Lugtenberg, D Cohen, MJP Welters, I Ehsan, ...
Nature communications 11 (1), 3083, 2020
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
MJ Welters, TC van der Sluis, H van Meir, NM Loof, VJ van Ham, ...
Science translational medicine 8 (334), 334ra52-334ra52, 2016
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry
SJAM Santegoets, EM Dijkgraaf, A Battaglia, P Beckhove, CM Britten, ...
Cancer Immunology, Immunotherapy 64, 1271-1286, 2015
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...
Annals of oncology 33 (12), 1250-1268, 2022
Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05)
EJ Blok, JR Kroep, E Meershoek-Klein Kranenbarg, ...
JNCI: Journal of the National Cancer Institute 110 (1), 40-48, 2018
Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial …
TJA Dekker, CJH Van De Velde, GW Van Pelt, JR Kroep, JP Julien, ...
Breast cancer research and treatment 139, 371-379, 2013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20